Tandem Diabetes Care, Inc. (TNDM) has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA). The partnership will focus on advancing research and development efforts on fully automated closed-loop insulin delivery systems.Tandem Diabetes’ previous work with UVA, including research related to its automated insulin delivery systems as part of the International Diabetes Closed Loop trials, has resulted in life-changing products for the diabetes communi ...

Tandem Diabetes Care, Inc. (TNDM) announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s (DXCM) G7 and G6 Continuous Glucose Monitoring (“CGM”) systems. This follows Health Canada’s sale authorization in July 2024, making t:slim X2 with Control-IQ technology the first and only insulin pump in Canada to be integrated with both systems.The commercial availability of this new offering reflects the decade-long partnership between the two ...

Tandem Diabetes Care, Inc. (TNDM) posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s reported loss of 38 cents. The figure beat the Zacks Consensus Estimate of a loss of 43 cents per share.On a GAAP basis, the loss was 35 cents per share compared with the year-ago loss of 51 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, TNDM stock fell 2% in aftermarket trading yesterday. TNDM’s Q3 RevenuesGAAP reven ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Susan Morrison - EVP and Chief Administrative Officer. John Sheridan - President and CEO Leigh Vosseller - EVP and CFO Conference Call Participants Mathew Blackman - Stifel Steve Lichtman - Oppenheimer & Company Brooks O'Neil - Lake Street Capital Markets Matt Miksic - Barclays Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Patrick Wood - Morgan Stanley Matt Taylor - Jeff ...

For the quarter ended September 2024, Tandem Diabetes Care, Inc. (TNDM) reported revenue of $243.97 million, up 31.4% over the same period last year. EPS came in at -$0.36, compared to -$0.38 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $223.33 million, representing a surprise of +9.24%. The company delivered an EPS surprise of +16.28%, with the consensus EPS estimate being -$0.43.While investors closely watch year-over-year changes in headline numbers -- revenue ...

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this company would post a loss of $0.54 per share when it actually produced a loss of $0.47, delivering a surprise of 12.96%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the T ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Third Quarter 2024 Highlights Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance San Diego, November 6, 2024 - Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales ...

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has experienced a significant decline of 21.7% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Stock Performance and Indicators - TNDM's Relative Strength Index (RSI) reading is at 29.87, indicating that the heavy selling pressure may be exhausting, suggesting a possible bounce back towards previous supply and demand equilibrium [3]. - The stock is considered oversold when its RSI falls below 30, which is a common threshold for identifying potential price reversals [2]. Group 2: Earnings Estimates and Analyst Consensus - There is strong consensus among sell-side analysts that earnings estimates for TNDM have increased by 0.1% over the last 30 days, indicating a positive outlook for the company's financial performance [4]. - TNDM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [4].

Flat revenue growth might be in store for the company in a very crucial market. An analyst issued the equivalent of a warning on Tandem Diabetes Care (TNDM -3.16%) stock on the second trading day of the week and, absent any other news for the company, some investors traded out of it. This left Tandem's shares with a more than 3% loss in price on the day, which compared unfavorably to the sub-1% decline of the bellwether S&P 500 index. Citi advises keeping watch on the stock The prognosticator behind that pi ...